Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA
Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.
FDA issued an Early Alert notifying the public of a potentially high-risk device issue with GE HealthCare Infant Resuscitation Systems, recommending affected devices be corrected prior to continued use.
The issue could lead to hypoxia or hyperoxia in infant patients if the device delivers incorrect oxygen concentration.
Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.
Regulatory Intelligence Lead
as needed until resolved
Follow the instructions in the alert.
Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.
FDA issued an early alert on June 5, 2026, concerning GE HealthCare Infant Resuscitation Systems and Warmers with M1091607-R blender. The knob shaft may loosen, causing oxygen concentration mismatch and potential hypoxia or hyperoxia. No serious injuries or deaths reported as of May 20, 2026.
What changed: FDA issued an Early Alert notifying the public of a potentially high-risk device issue with GE HealthCare Infant Resuscitation Systems, recommending affected devices be corrected prior to continued use.
Why it matters: The issue could lead to hypoxia or hyperoxia in infant patients if the device delivers incorrect oxygen concentration.
Practical implication: Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.
Published from the Firecrawl agent regulatory extraction pipeline.
Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.
Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.
Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.
Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.